Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials

Yukio TanizawaYamaguchi University Graduate School of Medicine, Division of Endocrinology, Metabolism, Hematological Science and Therapeutics, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan+81 836 22 2250 (office); +81 836 22 2256; [email protected]

, MD PhD,

Kohei KakuKawasaki Medical School, Department of Internal Medicine, Kurashiki, Japan

, MD PhD,

Eiichi ArakiKumamoto University, Faculty of Life Sciences, Department of Metabolic Medicine, Kumamoto, Japan

, MD PhD,

Kazuyuki TobeUniversity of Toyama, The First Department of Internal Medicine, Toyama, Japan

, MD PhD,

Yasuo TerauchiYokohama City University, Graduate School of Medicine, Department of Endocrinology and Metabolism, Yokohama, Japan

, MD PhD,

Kazunori UtsunomiyaJikei University School of Medicine, Department of Internal Medicine, Division of Diabetes, Metabolism and Endocrinology, Tokyo, Japan

, MD PhD,

Yasuhiko IwamotoTokyo Women's Medical University School of Medicine, Tokyo, Japan

, MD PhD,

Hirotaka WatadaJuntendo University Graduate School of Medicine, Department of Endocrinology & Metabolism, Tokyo, Japan

, MD PhD,

Wataru OhtsukaChugai Pharmaceutical Co., Ltd, Clinical Research Planning Department, Tokyo, Japan

Daisuke WatanabeSanofi K.K., Research & Development, Clinical Sciences & Operations, Biostatistics & Programming, Biostatistics, Tokyo, Japan

, PhD,

Hideki SuganamiKowa Co., Ltd, Clinical Data Science Department, Biostatistics Section, Tokyo, Japan

, PhD & for the Tofogliflozin 004 and 005 Study group show all

Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date